CN1507353A - 用于治疗IgE相关性疾病的组合物 - Google Patents

用于治疗IgE相关性疾病的组合物 Download PDF

Info

Publication number
CN1507353A
CN1507353A CNA018232426A CN01823242A CN1507353A CN 1507353 A CN1507353 A CN 1507353A CN A018232426 A CNA018232426 A CN A018232426A CN 01823242 A CN01823242 A CN 01823242A CN 1507353 A CN1507353 A CN 1507353A
Authority
CN
China
Prior art keywords
ige
compositions
treatment
antigen
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA018232426A
Other languages
English (en)
Chinese (zh)
Inventor
T
T·胡尔奇
Ͳ
J·布劳布格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1507353A publication Critical patent/CN1507353A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CNA018232426A 2001-05-11 2001-05-11 用于治疗IgE相关性疾病的组合物 Pending CN1507353A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2001/005412 WO2002092125A1 (en) 2001-05-11 2001-05-11 Compositions for use in treating ige-associated disorders

Publications (1)

Publication Number Publication Date
CN1507353A true CN1507353A (zh) 2004-06-23

Family

ID=8164413

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA018232426A Pending CN1507353A (zh) 2001-05-11 2001-05-11 用于治疗IgE相关性疾病的组合物

Country Status (7)

Country Link
US (1) US20050031609A1 (enExample)
EP (1) EP1390067A1 (enExample)
JP (1) JP2004529180A (enExample)
CN (1) CN1507353A (enExample)
BR (1) BR0117009A (enExample)
CA (1) CA2446108A1 (enExample)
WO (1) WO2002092125A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114504644A (zh) * 2021-12-24 2022-05-17 北京大学第一医院 抗IgE抗体在用于治疗腺样体肥大中的应用

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026881A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
KR20060096030A (ko) * 2003-09-17 2006-09-05 베이비 부스트 인코퍼레이티드 알레르기 방지 방법 및 기구
ES2379267T3 (es) * 2003-10-23 2012-04-24 Novartis Vaccines And Diagnostics, Inc. Composiciones estabilizadas
ATE524561T1 (de) * 2004-04-06 2011-09-15 Sinai School Medicine Verfahren zur bestimmung einer allergenreaktion unter verwendung von mikroarray-immunoassay- techniken
JP2006137678A (ja) * 2004-11-10 2006-06-01 Shionogi & Co Ltd インターロイキン−２組成物
WO2007095230A2 (en) * 2006-02-13 2007-08-23 The Trustees Of The University Of Pennsylvania TREATMENT OF AUTOIMMUNE BLISTERING DISEASE USING ANTI-IgE ANTIBODY
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
KR102502640B1 (ko) 2012-08-21 2023-02-23 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
CN118286417A (zh) 2012-09-07 2024-07-05 瑞泽恩制药公司 以il-4r拮抗剂治疗特应性皮炎的方法
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
PT3110848T (pt) 2014-09-24 2024-03-05 Regeneron Pharma Métodos para tratamento de infeção cutânea por administração de um antagonista do il-4r
CA3246946A1 (en) 2014-11-14 2025-11-29 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
KR102872485B1 (ko) 2016-09-01 2025-10-20 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
US11034768B2 (en) 2017-10-30 2021-06-15 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
MX2020012064A (es) 2018-05-13 2021-04-13 Regeneron Pharma Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r.
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
KR20220034878A (ko) 2019-07-16 2022-03-18 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
US11504426B2 (en) 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
JP7736667B2 (ja) 2019-08-05 2025-09-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４ｒアンタゴニストを投与することによるアトピー性皮膚炎の治療方法
WO2025010086A1 (en) 2023-07-05 2025-01-09 Genentech, Inc. Anti-ige antibody therapy for multiple food allergies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
AP660A (en) * 1994-01-18 1998-08-18 Genentech Inc A method of treatment of parasitic infection using IgE antagonists.
JP2003524602A (ja) * 1998-09-18 2003-08-19 ダイナバックス テクノロジーズ コーポレイション ＩｇＥ関連疾患の治療方法と、その治療において使用する組成物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114504644A (zh) * 2021-12-24 2022-05-17 北京大学第一医院 抗IgE抗体在用于治疗腺样体肥大中的应用
CN114504644B (zh) * 2021-12-24 2024-02-13 北京大学第一医院 抗IgE抗体在用于治疗腺样体肥大中的应用

Also Published As

Publication number Publication date
BR0117009A (pt) 2004-04-20
JP2004529180A (ja) 2004-09-24
US20050031609A1 (en) 2005-02-10
EP1390067A1 (en) 2004-02-25
CA2446108A1 (en) 2002-11-21
WO2002092125A1 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
US20050031609A1 (en) Compositions for use in treating ige-associated disorders
JP2004529180A5 (enExample)
RU2587061C2 (ru) Способы лечения аллергических заболеваний
CN1202863C (zh) 包含作为佐剂的甘油单酯或甘油二酯衍生物的抗原释放系统
CA2554337A1 (en) Methods and compositions for dosing of allergens
HK1200019A1 (en) Use of a liquid allergy vaccine formulation for oromucosal administration
WO2008153761A1 (en) Methods
EP3506921B1 (en) Depot systems comprising glatiramer acetate
JP2005515198A5 (enExample)
WO2024067874A1 (zh) 一种改性壳聚糖及其在大分子活性成分递送中的应用
CN101111265A (zh) Xolair/Omalizumab/E25与免疫抑制剂的协同组合
US20150246015A1 (en) Esters of Short Chains Fatty Acids for Use in the Treatment of Immunogenic Disorders
CN1543338A (zh) 壳多糖微粒及其医疗用途
Rolland et al. Allergen immunotherapy: current and new therapeutic strategies
CN1612751A (zh) 包括施用抗IgE抗体和抗过敏化合物、用于过敏性疾病的组合治疗
JPS63277634A (ja) アレルギーの治療およびそのための組成物
JP2019530702A (ja) アレルギーの予防
Bidad et al. A review of allergy and allergen specific immunotherapy
US9585954B2 (en) Mucosal immunization
EP2442828B1 (en) Novel manner of administrating allergen in allergen specific immunotherapy
US20050143473A1 (en) Methods for treating allergy
HK1066165A (en) Compositions for use in treating ige-associated disorders
Pajnoª et al. Efficacy of Sublingual Immunotherapy in
CN1108095A (zh) 用于预防和治疗近视的组合物
US20060269576A1 (en) Non-injection immunotherapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1066165

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1066165

Country of ref document: HK